CD105 (endoglin)-negative murine mesenchymal stromal cells define a new multipotent subpopulation with distinct differentiation and immunomodulatory capacities.
Administration of in vitro expanded mesenchymal stromal cells (MSCs) represents a promising therapy for regenerative medicine and autoimmunity.Both mouse and human MSCs ameliorate autoimmune disease in syn-, allo- and xenogeneic settings.However, MSC preparations are heterogeneous which impairs their therapeutic efficacy and endorses variability be